VEGFA and glioblastoma: On such study was conducted by Kloepper et al., in which they showed that Vanucizumab, which targets vascular endothelial growth factor (VEGF) and angiopoietin-2, repolarized microglia toward an M1 anti-tumoral phenotype that ultimately improved the survival time of grafted mice and helped delay GBM growth [67,88].